115 related articles for article (PubMed ID: 15329835)
1. Fetal toxicity of valsartan and possible reversible adverse side effects.
Berkane N; Carlier P; Verstraete L; Mathieu E; Heim N; Uzan S
Birth Defects Res A Clin Mol Teratol; 2004 Aug; 70(8):547-9. PubMed ID: 15329835
[TBL] [Abstract][Full Text] [Related]
2. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.
Bos-Thompson MA; Hillaire-Buys D; Muller F; Dechaud H; Mazurier E; Boulot P; Morin D
Ann Pharmacother; 2005 Jan; 39(1):157-61. PubMed ID: 15590878
[TBL] [Abstract][Full Text] [Related]
3. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].
Roger N; Popovic I; Madelenat P; Mahieu-Caputo D
Gynecol Obstet Fertil; 2007 Jun; 35(6):556-60. PubMed ID: 17544313
[TBL] [Abstract][Full Text] [Related]
4. Fatal fetal outcome with the combined use of valsartan and atenolol.
Briggs GG; Nageotte MP
Ann Pharmacother; 2001; 35(7-8):859-61. PubMed ID: 11485133
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor blocker induced fetopathy: 7 cases.
Hünseler C; Paneitz A; Friedrich D; Lindner U; Oberthuer A; Körber F; Schmitt K; Welzing L; Müller A; Herkenrath P; Hoppe B; Gortner L; Roth B; Kattner E; Schaible T
Klin Padiatr; 2011 Jan; 223(1):10-4. PubMed ID: 21271514
[TBL] [Abstract][Full Text] [Related]
7. Severe neonatal renal failure after maternal use of angiotensin II type I receptor antagonists.
Sinelli MT; Cattarelli D; Cortinovis S; Maroccolo D; Chirico G
Pediatr Med Chir; 2008; 30(6):306-8. PubMed ID: 19431954
[TBL] [Abstract][Full Text] [Related]
8. Fetal toxic effects and angiotensin-II-receptor antagonists.
Martinovic J; Benachi A; Laurent N; Daikha-Dahmane F; Gubler MC
Lancet; 2001 Jul; 358(9277):241-2. PubMed ID: 11480433
[No Abstract] [Full Text] [Related]
9. Valsartan. Just a second-line antihypertensive drug.
Can Fam Physician; 1999 Nov; 45():2626-8, 2630-3. PubMed ID: 10587770
[TBL] [Abstract][Full Text] [Related]
10. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension.
Watanabe S; Okura T; Kurata M; Irita J; Manabe S; Miyoshi K; Fukuoka T; Gotoh A; Uchida K; Higaki J
Clin Exp Hypertens; 2006 Jul; 28(5):451-61. PubMed ID: 16820342
[TBL] [Abstract][Full Text] [Related]
11. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
Yang HY; Kao PF; Chen TH; Tomlinson B; Ko WC; Chan P
J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
[TBL] [Abstract][Full Text] [Related]
12. Increased renal echogenicity in a preterm neonate. Kidneys with tubular dysplasia due to exposure to candesartan during pregnancy.
Bald M; Holder M; Zieger M; Vochem M; Leichter HE
Pediatr Nephrol; 2005 Nov; 20(11):1664-5, 1666-8. PubMed ID: 16082550
[No Abstract] [Full Text] [Related]
13. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.
Biswas PN; Wilton LV; Shakir SW
J Hum Hypertens; 2002 Nov; 16(11):795-803. PubMed ID: 12444541
[TBL] [Abstract][Full Text] [Related]
14. A drug safety evaluation of valsartan.
Fogari R; Zoppi A
Expert Opin Drug Saf; 2011 Mar; 10(2):295-303. PubMed ID: 21142805
[TBL] [Abstract][Full Text] [Related]
15. Valsartan in chronic heart failure.
Ripley TL
Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
[TBL] [Abstract][Full Text] [Related]
16. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
[TBL] [Abstract][Full Text] [Related]
17. Temporal association as a prerequisite factor of valsartan-induced lithium toxicity.
Lazarczyk MJ; Giannakopoulos P
Bipolar Disord; 2014 Sep; 16(6):662-6. PubMed ID: 24372930
[TBL] [Abstract][Full Text] [Related]
18. Valsartan-induced acute pancreatitis.
Can B; Sali M; Batman A; Yilmaz H; Korkmaz U; Celebi A; Senturk O; Hulagu S
Intern Med; 2014; 53(7):703-5. PubMed ID: 24694480
[TBL] [Abstract][Full Text] [Related]
19. Exanthematous drug eruption due to valsartan.
Ozturk G; Turk BG; Senturk B; Turkmen M; Kandiloglu G
Cutan Ocul Toxicol; 2012 Dec; 31(4):335-7. PubMed ID: 22257082
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
